A Phase 4 interventional study of Tirzepatide as an adjunct to lifestyle intervention and Placebo as an adjunct to lifestyle intervention in Polycystic Ovary Syndrome (PCOS) and Obesity & Overweight, sponsored by University of Bonn. Recruiting at 2 sites in Germany. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by University of Bonn · Phase 4, Interventional, and Treatment
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical study examines whether tirzepatide can improve ovarian dysfunction in premenopausal women with polycystic ovary syndrome (PCOS) who are overweight or have obesity. Tirzepatide is already approved for the treatment of diabetes and obesity, but its effects on ovarian dysfunction in PCOS are not yet known. Participants will be randomly assigned to tirzepatide or placebo in a double-blinded manner.
The goal of the study is to demonstrate that tirzepatide, at the maximum tolerated dose, is superior to placebo for improvement of ovarian dysfunction as defined by menstrual irregularity in overweight or obesity-related PCOS.
All participants will have a screening visit, followed by 72 weeks of treatment. Treatment includes a 20-week dose-escalation period and a 52-week maintenance period. Lower doses may be used if side effects occur, and the highest tolerated dose will be continued through the maintenance phase. A 4-week safety follow-up will take place after treatment, and long-term follow-up will continue for one year. The study will take place at five clinical trial sites in Germany.
PERIODS is a prospective, phase IV, multi-centre, randomized, double-blind and placebo-controlled clinical trial that will investigate the effects of tirzepatide compared with placebo on ovarian dysfunction in premeno-pausal, overweight (BMI ≥ 27 kg/m2) women with PCOS. The primary endpoint is the improvement of ovarian dysfunction as defined by menstrual irregularity and ovulation frequency in overweight or obesity-related PCOS.
All subjects will undergo a screening visit and a 72-week treatment period including a 20-week dose escalation up to the maximum tolerated dose. Lower doses of tirzepatide are permitted if intolerable side effects occur. However, even if a lower dose of tirzepatide turns out to be the maximum tolerated dose, this lower dose will be administered for the entire 20-week dose escalation period, followed by the 52-week maintenance dose.
The safety follow-up period will be 4 weeks (for subjects completing or discontinuing IMP during the first 72 weeks). Long-term follow-up will be one year after discontinuation of IMP.
The trial design is multi-centred with a planned number of 5 participating trial sites in Germany.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
This study's planned enrollment of 198 is above the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Browse Polycystic Ovary Syndrome studies →University of Bonn is the lead sponsor of 39 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
General Inclusion Criteria
Subjects
Indication-specific Inclusion Criteria
General Exclusion Criteria
Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the trial results, or may interfere with the subject's participation in this clinical trial
History of an active or untreated or being in remission from a malig-nancy for less than 5 years
o Excluding basal- or squamous-cell skin cancer or in situ carcinomas of the cervix
Indication-specific Exclusion Criteria
Prior diagnosis of diabetes mellitus other forms than type 2
o Note: Excluding prior history of gestational diabetes
In case of diabetes mellitus type 2, exclusion of subjects
Thyroid, pituitary, and/or adrenal disease (if not appropriately treated)
o Note: Excluding stable disease and/or stable drug dose 12 weeks before screening
Elevated calcitonin levels as determined by the laboratory during screening
Previous or planned bariatric surgery or endoscopic and/or device-based therapy for obesity
o Note: excluding liposuction or abdominoplasty if performed > 1 year prior to screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly abdominal subcutaneous injection of tirzepatide over a 72-week treatment period including a 20-week dose-escalating regiment and 52-week treatment period adjunct to reduced-calorie diet and increased physical activity
Drug: Tirzepatide as an adjunct to lifestyle intervention
Weekly abdominal subcutaneous injection of a placebo injectable over a 72-week period ad-junct to reduced-calorie diet and increased physical activity.
Drug: Placebo as an adjunct to lifestyle intervention
Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg Mode of application: weekly subcutaneous injection, prefilled pen injector Duration of treatment: 72 weeks (20 weeks dose escalation, 52 weeks treatment with maximum tolerated dose)
Dose: Placebo Pens to mimic doses 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg Mode of Application: weekly subcutaneous injection, prefilled pen injector Duration of Treatment: 72 weeks
This study also gives TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Improvement of ovarian dysfunction as defined by menstrual irregularity in overweight or obesity-related PCOS
1. Mean menstrual bleeding ratio (number of menstrual bleedings divided by treatment period in months) during the last 52 weeks of treatment, assessed at 72 weeks after randomization 2. Mean change in menstrual bleeding ratio from baseline, calculated at 72 weeks after randomization (with baseline defined as mean menstrual bleeding ratio during the 6 months before randomization)
Time frame: At 72 weeks after randomization
Key Secondary - Improvement of ovarian dysfunction as defined by ovulation frequency in overweight or obesity-related PCOS
Total number of biochemically confirmed ovulatory events (within 24 weeks after completed dose titration) measured by weekly serum progesterone
Time frame: Within 24 weeks after completed dose titration
Percentage of Participants With Normalization of Menstrual Cycle
Normalization of the menstrual cycle is defined as a cycle length greater than 21 days and less than 35 days, or more than 8 cycles per year. This endpoint compares the proportion of subjects achieving this criteria in the tirzepatide group versus the placebo group.
Time frame: Week 72
Change From Baseline in Serum Anti-Müllerian Hormone (AMH)
Assessment of AMH as a surrogate marker for ovarian follicle pool and ovarian morphology.
Time frame: Baseline and Week 72
Change From Baseline in Biochemical Androgen Profile
Evaluation of the androgenic status including Total Testosterone, Sex Hormone-Binding Globulin (SHBG), DHEA-S, and Androstenedione. Results will be reported as the change from baseline or the ratio of Week 72 to baseline.
Time frame: Baseline and Week 72
Change From Baseline in Calculated Free Androgen Index (FAI) and Calculated Free Testosterone
FAI is calculated as (Total Testosterone/SHBG) x 100. Free Testosterone is calculated using the Vermeulen formula or a similar validated method based on Total Testosterone and SHBG levels.
Time frame: Baseline and Week 72
Change From Baseline in Pituitary-Gonadal Hormones (LH, FSH, Estradiol, Progesterone)
Assessment of the hormonal regulation of the ovarian cycle by measuring Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), Estradiol, and Progesterone.
Time frame: Baseline and Week 72
Percentage Change in Body Weight from Baseline to Week 72
Relative change in total body weight compared to the starting weight.
Time frame: Baseline and Week 72
Percentage of Participants Achieving ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% Body Weight Loss
Proportion of subjects in each treatment arm who reach the specified weight loss thresholds at Week 72.
Time frame: Baseline and Week 72
Change from Baseline in Body Composition (BIA) at Week 72
Mean change in fat mass and fat-free mass as measured by Bioelectrical Impedance Analysis (BIA).
Time frame: Baseline and Week 72
Change from Baseline in Waist Circumference and Waist-to-Hip Ratio
Measurement of abdominal fat distribution change from randomization to Week 72.
Time frame: Baseline and Week 72
Change from Baseline in Fasting Glucose and HbA1c at Week 72
Assessment of long-term and fasting glycemic control.
Time frame: Baseline and Week 72
Change from Baseline in Systemic Insulin Sensitivity Indices
Evaluation of insulin sensitivity using the Quantitative Insulin Sensitivity Check Index (QUICKI), Homeostasis Model Assessment (HOMA-IR), and Matsuda's Insulin-Sensitivity Index derived from OGTT data.
Time frame: Baseline and Week 72
Change from Baseline in Fasting Lipid Profile at Week 72
Mean change in Triglycerides and the Triglyceride-to-HDL Ratio.
Time frame: Baseline and Week 72
Change from Baseline in Fasting Lipid Profile at Week 72
Mean change in Total Cholesterol, LDL Cholesterol and HDL cholesterol
Time frame: Baseline and Week 72
Change from Baseline in Liver Enzymes and Non-invasive Biomarkers (FLI, FIB-4)
Assessment of liver health via Fatty Liver Index (FLI) and FIB-4 Score.
Time frame: Baseline and Week 72
Change from Baseline in Liver Stiffness and Fat Content at Week 72
Measurement of hepatic steatosis and fibrosis via imaging (e.g., Transient Elastography/FibroScan).
Time frame: Baseline and Week 72
Change from Baseline in Systolic and Diastolic Blood Pressure
Mean change in SBP and DBP from randomization to Week 72.
Time frame: Baseline and Week 72
Change from Baseline in High-Sensitivity C-Reactive Protein (hs-CRP)
Marker for systemic meta-inflammation.
Time frame: Baseline and Week 72
Change From Baseline in the 36-Item Short Form Survey (SF-36) at Week 72
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores. Each scale is transformed to a 0-100 range, where 0 indicates the lowest level of health and 100 indicates the highest level of health (higher scores mean a better outcome).
Time frame: Baseline and Week 72
Change From Baseline in the Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ)
The PCOSQ measures health-related quality of life in women with PCOS across five domains (Emotions, Body Hair, Weight, Infertility, and Menstrual Problems). Each item is scored on a 7-point scale. Domain scores range from 1 to 7, where higher scores indicate better health-related quality of life/less distress.
Time frame: Baseline and Week 72
Change From Baseline in the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L)
The EQ-5D-5L consists of a descriptive system (5 dimensions) and a Visual Analogue Scale (VAS). The VAS records the respondent's self-rated health on a vertical scale where the endpoints are labeled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). Higher scores mean a better outcome.
Time frame: Baseline and Week 72
Patient Global Impression of Severity (PGI-S) at Week 72
The PGI-S is a single-item question asking the patient to rate the severity of their condition. It uses a 5-point scale: 1 (None), 2 (Mild), 3 (Moderate), 4 (Severe), 5 (Very Severe). A decrease in score indicates an improvement in condition.
Time frame: Baseline and Week 72
Dose-Dependent Menstrual Bleeding Ratio at Week 72
Evaluation of the dose-response relationship of tirzepatide (5 mg, 10 mg, and 15 mg) compared to placebo. Mean menstrual bleeding ratio at 72 weeks after randomization.
Time frame: Week 72
Dose-Dependent Change in Mean Menstrual Bleeding Ratio at Week 72
Evaluation of the dose-response relationship of tirzepatide (5 mg, 10 mg, and 15 mg) compared to placebo. Mean change in menstrual bleeding ratio at 72 weeks after randomization
Time frame: Baseline and Week 72
Dose-Dependent Normalization of Menstrual Cycle
Evaluation of the dose-response relationship (5 mg, 10 mg, and 15 mg) compared to placebo. Percentage of subjects achieving a cycle length \> 21 and \< 35 days or \> 8 cycles/year.
Time frame: 72 weeks
Total Number of Biochemically Confirmed Ovulatory Events (Dose-Response)
Evaluation of the dose-response relationship (5 mg, 10 mg, and 15 mg) compared to placebo. Number of ovulatory events (serum progesterone ≥ 3 ng/mL) during the 24 weeks following completed dose titration.
Time frame: 24 weeks following completed dose titration
Change From Baseline in Ovarian Volume (MTD vs. Placebo)
Change in ovarian volume (OV) measured by transvaginal ultrasound, comparing the maximum tolerated dose (MTD) of tirzepatide to placebo.
Time frame: 72 weeks
Change From Baseline in Follicle Number Per Ovary (MTD vs. Placebo)
Change in follicle number per ovary (FNPO) measured by transvaginal ultrasound (MTD vs. placebo).
Time frame: 72 weeks
Change From Baseline in Hirsutism (Ferriman-Gallwey Score) at MTD
Assessment of hair growth using the modified Ferriman-Gallwey score. Scale: 0 (no hair) to 36 (severe hirsutism). A decrease in score indicates improvement.
Time frame: 72 weeks
Change From Baseline in Female Pattern Baldness (Ludwig Scale) at MTD
Assessment using the Ludwig scale (Grade I, II, or III). Higher grades indicate more severe hair loss. A decrease in grade indicates improvement.
Time frame: 72 weeks
Change From Baseline in Acne Lesion Count at MTD
Count of acne spots per side of the face (MTD vs. placebo).
Time frame: 72 weeks
Percentage of Participants Reaching HbA1c Targets (< 7% and < 6.5%) at MTD
Proportion of diabetic participants reaching glycemic targets (MTD vs. placebo).
Time frame: 72 weeks
Change From Baseline in HbA1c at MTD
Mean change in HbA1c (%) from randomization to Week 72 (MTD vs. placebo).
Time frame: 72 weeks
Menstrual Bleeding Ratio Within 52 Weeks After Drug Discontinuation
Mean bleeding ratio calculated during the off-drug period (Week 72 to Week 124).
Time frame: Week 124
Change in Menstrual Bleeding Ratio (Treatment vs. Follow-up)
Comparison of the bleeding ratio during the treatment phase (up to Week 72) versus the bleeding ratio during the 52-week follow-up phase (Week 124).
Time frame: Week 72 to Week 124
Percentage of Participants Maintaining Menstrual Cycle Normalization at Week 124
Proportion of participants who still meet the criteria for normal cycles (21-35 days or \>8/year) 52 weeks after stopping tirzepatide.
Time frame: Week 124
Change From Baseline in Ovarian Volume (OV) and Follicle Number (FNPO) at Week 124
Assessment of sustained effects on ovarian morphology via transvaginal ultrasound 52 weeks after drug discontinuation.
Time frame: Baseline and Week 124
Change From Baseline in Serum Anti-Müllerian Hormone (AMH) at Week 124
Evaluation of AMH levels as a marker of ovarian reserve and morphology after the 52-week follow-up period.
Time frame: Baseline and Week 124
Change From Baseline in Androgen Profile and Gonadotropins at Week 124
Includes Total Testosterone, Estradiol, Progesterone, SHBG, DHEA-S, Androstenedione, LH, and FSH measured 52 weeks after drug discontinuation.
Time frame: Baseline and Week 124
Change From Baseline in Calculated Free Androgen Index (FAI) and Free Testosterone at Week 124
Calculation of FAI \[(Total Testosterone/SHBG) x 100\] and free testosterone to assess sustained biochemical improvement after drug discontinuation.
Time frame: Baseline and Week 124
Sustained Improvement in Hirsutism (Ferriman-Gallwey Score) at Week 124
mFG score (range 0-36, higher score = more severe) measured 52 weeks after drug discontinuation. A lower score compared to baseline indicates sustained improvement.
Time frame: Baseline and Week 124
Sustained Improvement in Female Pattern Baldness (Ludwig Scale) and Acne at Week 124
Assessment of hair loss (Ludwig Grade I-III) and acne lesion counts (number of spots) at the end of the follow-up period.
Time frame: Baseline and Week 124
Clinical Pregnancy Rate at Week 124
Percentage of subjects who achieve clinical pregnancy (confirmed by ultrasound visualization of fetal cardiac activity) after drug discontinuation. This includes conception via natural/spontaneous means, pharmacologically induced ovulation (e.g., letrozole, clomiphene), or Assisted Reproductive Technology (ART).
Time frame: From Week 72 to Week 124
Change From Baseline in Body Weight and Composition at Week 124
Mean and percentage change in body weight, fat mass, and fat-free mass (measured by BIA) 52 weeks after drug discontinuation.
Time frame: Baseline and Week 124
Percentage of Participants Maintaining Weight Loss Thresholds at Week 124
Proportion of participants maintaining ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% weight loss from randomization at the end of the follow-up period.
Time frame: Week 124
Change From Baseline in Waist Circumference and Waist-to-Hip Ratio at Week 124
Assessment of abdominal fat distribution 52 weeks after drug discontinuation.
Time frame: Baseline and Week 124
Change From Baseline in Fasting Glucose and HbA1c at Week 124
Change From Baseline in Fasting Glucose and HbA1c at Week 124
Time frame: Baseline and Week 124
Change From Baseline in Insulin Sensitivity Indices (QUICKI, HOMA-IR, Matsuda) at Week 124
Derived from fasting and OGTT data to assess sustained effects on insulin sensitivity.
Time frame: Baseline and Week 124
Change From Baseline in Fasting Lipid Parameters at Week 124
Assessment of sustained effects on total cholesterol, HDL and LDL cholesterol 52 weeks after drug discontinuation.
Time frame: Baseline and Week 124
Change From Baseline in Fasting Lipid Parameters at Week 124
Assessment of sustained effects and Change From Baseline in fasting triglycerides and Triglyceride-to-HDL Cholesterol Ratio 52 weeks after drug discontinuation.
Time frame: Baseline and Week 124
Change From Baseline in Liver Enzymes at Week 124
Mean change in serum levels of liver enzymes (e.g., ALT, AST, GGT) to assess sustained hepatic safety and function 52 weeks after drug discontinuation.
Time frame: Baseline and Week 124
Change From Baseline in Non-invasive Liver Scores (FLI and FIB-4) at Week 124
Evaluation of the Fatty Liver Index (FLI) and the Fibrosis-4 (FIB-4) score 52 weeks after drug discontinuation.
Time frame: Baseline and Week 124
Change From Baseline in Blood Pressure
Assessment of sustained effects on systolic/diastolic BP
Time frame: Baseline and 124 weeks
Change From Baseline in hs-CRP at Week 124
Assessment of sustained effects on systemic meta-inflammation (hs-CRP).
Time frame: Baseline and week 124
Change From Baseline in the 36-Item Short Form Survey (SF-36) at Week 124
The SF-36 is a health survey yielding scores from 0 to 100. Higher scores indicate a better health-related quality of life. Assessment of sustained well-being 52 weeks after drug discontinuation.
Time frame: Baseline and Week 124
Change From Baseline in the PCOS Health-Related Quality of Life Questionnaire (PCOSQ) at Week 124
The PCOSQ measures five domains (Emotions, Body Hair, Weight, Infertility, Menstrual Problems) on a scale of 1 to 7. Higher scores indicate better health-related quality of life.
Time frame: Baseline and Week 124
Change From Baseline in EQ-5D-5L Health State Index Score at Week 124
The EQ-5D-5L Index Score is derived from 5 dimensions (Mobility, Self-care, Usual activities, Pain/discomfort, and Anxiety/depression). Each dimension has 5 levels. The scores are converted into a single index value using a country-specific value set (e.g., German Value Set). The index score ranges from less than 0 (where 0 is death) to 1 (perfect health). Higher scores indicate a better health state.
Time frame: Baseline and Week 124
Patient Global Impression of Severity (PGI-S) at Week 124
A single-item scale where patients rate their disease severity from 1 (None) to 5 (Very Severe). A decrease in score indicates improvement.
Time frame: Week 124
Plan to share: Yes — Individual subject data will be available. Individual subject data (including data dictionaries) that underlie results concerning primary or secondary endpoints reported in a published scientific article will be shared on demand after deidentification. Furthermore, the following documents will be made available at least: Trial Protocol and Informed Consent Form. The data will be shared immediately following publication and ending 10 years following publication. Data are made available to researchers after a methodologically sound scientific proposal has been submitted to the Coordinating Investigator, and a steering committee consisting of the Coordinating Investigator, the representative of the Coordinating Investigator, and an authorized SZB member has approved the proposal. The data will be shared to achieve aims in the approved proposal. Proposals should be directed to Wiebke.Fenske@rub.de. To gain access, data requestors will need to sign a data access agreement.
Time frame: The data will be shared immediately following publication and ending 10 years following publication.
Access criteria: To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.
Of 41 non-industry phase 4 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 45. This study's planned 36 months is above that.
Counting every sponsor, half of 42 studies reached it within 25 months; a quarter within 11 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide
University of Bonn